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ABSTRACT 
IMPACT OF BODYWEIGHT ON TISSUE-SPECIFIC FOLATE STATUS, GENOME 
WIDE AND GENE-SPECIFIC DNA METHYLATION IN NORMAL BREAST 
TISSUES FROM PREMENOPAUSAL WOMEN 
 
MAY 2018 
 
ARMINA-LYN FREDERICK, B.S., UNIVERSITY OF MASSACHUSETTS 
AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Zhenhua Liu 
 
Obesity has reached an epidemic level in the United States. A number of epidemiological 
studies have established obesity as a critical risk factor for postmenopausal breast cancer 
(post-BC), whereas a reverse association holds prior to menopause. A significant 
scientific gap exists in understanding the mechanism(s) underpinning this 
epidemiological phenomenon, particularly the reverse association between obesity and 
premenopausal breast cancer (pre-BC). This study aimed to understand how folate 
metabolism and DNA methylation informs the association between obesity and pre-BC. 
Fifty normal breast tissue samples were collected from premenopausal women who 
underwent reduction mammoplasty. We developed and measured the breast tissue folate 
by a Lactobacillus Casei microbiological assay, and the DNA methylation of LINE-1, a 
biomarker of genome-wide methylation, and the promoter methylation and gene 
expression of SFRP1, a tumor suppressor, were measured by pyrosequencing and real-
time PCR. We found a high BMI is associated with increased folate level in the 
mammary tissue, with an increase of 2.65 ng/g of folate per every 5-unit increase of BMI 
(p < 0.05). The LINE-1 DNA methylation was significantly associated with BMI (p < 
0.05), and marginally associated with folate concentration (p = 0.087).  For the 8 CpG 
 vi 
sites analyzed in the promoter region of the SFRP1 gene, no associations were observed 
for either BMI or tissue folate (p > 0.05), although a high expression of SFRP1 was 
observed in subjects with high BMI or high folate (p < 0.05). This study demonstrated 
that, in premenopausal women, obesity is associated with an increased mammary folate 
status, genome-wide DNA methylation and SFRP1 gene expression, indicating that the 
improved folate and epigenetic status is potentially responsible for the reverse association 
between obesity and pre-BC. More studies are warranted to further understand how 
obesity mediates pre-BC via altering folate metabolism and DNA methylation.  
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CHAPTER 1 
 
INTRODUCTION 
 
 
Breast cancer (BC) is the most commonly diagnosed cancer in women and the third 
leading cause of cancer-related death. (CDC 2017)  When compared to postmenopausal, 
premenopausal women with BC have poorer prognosis and respond less to chemotherapy.  
Within the same molecular subtypes, the signatures of genetic and epigenetic alterations 
are shown to be different in premenopausal versus postmenopausal BC. Tumors found in 
young women are biologically distinct from those found in women over 50 and may 
necessitate distinct preventive and therapeutic approaches. Obesity is an independent 
prognosis factor in BC. Unlike the positive association between obesity and 
postmenopausal BC risk, general adiposity exhibits an inverse effect with overall risk in 
premenopausal women. The mechanism for this protective effect is yet unknown. 
Epigenetic alterations occur well in advance of observable changes in DNA integrity or 
dysregulated cellular proliferation patterns. DNA hyper- or hypomethylation can be gene-
specific or genome-wide. Changes in the methylation levels of cytosine-guanine 
dinucleotide-rich areas (CpG sites), of tumor supressor or repair genes induce genomic 
instability; an early event in breast tumorigenesis. BMI and menopausal status have been 
shown to co-vary with gene-specific methylation patterns in BC. BMI is associated with 
hypermethylation levels of epiobesigenic genes governing critical cell functions across all 
molecular subtypes of BC.  
Though BMI is associated with lower global methylation levels overall, results 
from studies on global methylation, body weight status and BC risk are varied. This 
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variance may be due to heterogeneity between measurement assays. Global methylation as 
measured by LINE-1, a transposable element that composes more than 45% of the human 
genome, was positively associated with BMI in a recent cross-sectional study with a 
healthy cohort. A 2014 study by DeRoo et al. reported an association between LINE-1 
methylation from peripheral blood and BC risk in a dose-dependent manner. In a recent 
review, two out of the thirteen studies with significant results using LINE-1 found a 
reduced risk of BC with higher DNA methylation levels.  
Folate availability, the substrate for DNA methylation, may contribute to the 
potentially reversible epigenetic alterations associated with BC. Regardless of menopausal 
or weight status, epigenetic alterations resulting from deficiencies in one-carbon 
metabolism (OCM) related compounds such as folate have been shown to drive BC 
tumorigenesis. A deficiency in dietary folate has been shown to lead to gene promoter 
region hypermethylation as well as lower global hypomethylation. Epidemiological studies 
on the association between folate status and the risk of BC have shown inconsistent results. 
Meta-analyses suggest a U- or J-shaped curve relationship between folate intake and BC 
risk. A non-linear dose-response relationship between 200-320g/d of dietary folate and 
lower risk of BC was recently reported, verses a significant increase in risk with daily folate 
intakes above 400ug. In other prospective and case-control studies, dietary folate status as 
assessed between categories of highest and lowest intakes was not associated with a higher 
relative risk (RR) of BC for metastatic or invasive carcinoma. Conversely, when stratified 
into quartiles between lowest and highest intake as measured by a food frequency 
questionnaire (FFQ), folate was associated with an overall reduced RR of BC across all 
subtypes. A possible explanation to these mixed results could be timing or assessment 
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methods for measuring levels of folate intake. Folate’s role in BC etiology may depend 
heavily on age of dietary exposure. 
DNA methylation patterns differ between metabolic states, and fluctuations 
throughout the human lifespan of both folate status and BMI elicit modifiable changes in 
the epigenome. Epigenetic modifications are sensitive to folate availability and folate 
levels have been shown to change with BMI status. After adjustments for overall intake, 
overweight and obese women were reported to have lower serum folate and higher red 
blood cell (RBC) folate levels when compared to women of the same weight categories. In 
addition, BMI has been shown to affect the distribution of folate from circulation into 
tissue. This weight-dependent redistribution of folate may affect the availability of folate 
as a substrate for both global and gene-specific methylation. 
Whether changes in DNA methylation in response to folate levels and bodyweight 
are deleterious or protective against BC risk may heavily depend on menopausal status. 
Though the mechanisms underlying these associations have yet to be discovered, DNA 
methylation patterns in premenopausal overweight or obese women with BC are often 
significantly different from postmenopausal overweight or obese women with BC. Results 
from the few investigations on BMI, folate, methylation, menopausal status and BC risk 
are currently inconclusive. A possible explanation for these mixed results is that the 
relationship between these factors may be contingent on age, area of fat disposition, and 
metabolic activity of adipose. Despite the current lack of overall consensus, DNA 
methylation is highly associated with BMI and BMI status is associated with folate 
concentrations, when measured in adipose tissue. Weight-related differences between 
folate status as well as epigenetic responses to folate interventions provide significant 
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evidence in support of the effect of overweight and obesity on epiobesigenic methylation 
levels and BC risk. 
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CHAPTER 2  
LITERATURE REVIEW 
 
2.1 Breast Cancer 
Breast cancer chapter text. Aside from some skin cancers, breast cancer (BC) is the most 
frequently diagnosed cancer in women regardless of race or ethnicity. BC is the leading 
cause of cancer-related death in women aged 20-39 years. (CDC 2017) The American 
Cancer Society estimates that one in eight women in western countries will be diagnosed 
with BC during their lifetime. BC is projected to account for 30% of all new cancer cases, 
with about 255,180 new cases of invasive BC projected in 2018. It has been known since 
the mid-1980s that survival rates for all types of BC are significantly lower in 
premenopausal women versus postmenopausal. (Adami, Malker, Holmberg, Persson, & 
Stone, 1986) Younger age at onset is considered an independent risk factor for overall risk, 
tumor aggressiveness, recurrence and survival. (Bleyer et al., 2008; El Saghir et al., 2006) 
Rather than a single disease, BC is a collection of various subtypes with distinct 
underlying genetic profiles, molecular signatures and phenotypes. Instances of the most 
lethal subtype of BCs, such as triple negative, are higher in premenopausal women than 
in postmenopausal. (Anders, Johnson, Litton, Phillips, & Bleyer, 2009) Though incidence 
rate has remained relatively stable over the last decade, BC mortality rate in 
premenopausal women is slowly increasing. (Siegel, Miller, & Jemal, 2017) Common 
screening measures such as mammography are encouraged, as early detection has been 
shown to improve overall prognosis, yet these early stage events are often masked in 
mammograms of premenopausal women due to overall breast density. (Boyd et al., 2007) 
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Women with extensive mammographic density have a 17 times greater risk of developing 
BC within the 12 months following a negative screening due to this masking effect 
 
2.2 Obesity and Breast Cancer 
Well-established risk factors for BC are numerous. These risk factors include age; 
race and ethnicity; socioeconomic status; hormonal status and parity; breast density; diet, 
physical activity and body weight status. Of these modifiable and non-modifiable risk 
factors, body weight status is of high significance with regard to incidence and prognosis. 
(Calle, Rodriguez, Walker-Thurmond, & Thun, 2003). Body weight status as measured by 
body mass index (BMI), is significantly correlated with overall BC risk. (Tamimi et al., 
2016)  
Higher BMI, higher overall energy intake and lower physical activity levels have 
been associated with increased postmenopausal BC risk in prospective cohort studies. 
(Silvera, Jain, Howe, Miller, & Rohan, 2006) It was originally speculated that body 
weight status was also positively associated with the risk of premenopausal BC. (Silvera 
et al., 2006) However, in recent studies, though overweight or obese weight status (BMI 
of 25.0-29.9kg/m2 or 30kg/m2, respectively) has been continuously shown to be 
positively associated with postmenopausal BC risk, this correlation has been indicated to 
be reversed for women of childbearing age. (McCormack et al., 2006) In 2008, the 
Renehan laboratory reported their findings from a systematic review of meta-analysis of 
141 articles. The authors found that each 5 kg/m2 increase in BMI was associated with a 
12% increased RR of postmenopausal BC, versus an 8% decreased RR of premenopausal 
BC. (Renehan, Tyson, Egger, Heller, & Zwahlen, 2008) Findings from recent large-scale 
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epidemiologic studies also support a reverse relationship between overall weight status 
and premenopausal BC risk. (Munsell et al., 2014; Nelson et al., 2012) A meta-analysis 
of sixty-six studies conducted by Nelson et al. found an inverse association between 
premenopausal BC and metabolically healthy overweight/obese phenotype. In eighteen of 
the studies included in the meta-analysis, reduced risks were found for women in the 
overweight (RR, 0.86 [95% CI, 0.82, 0.90]) and obese (RR, 0.74 [CI, 0.68, 0.81]) BMI 
categories when compared to the reference group (normal and underweight combined). 
(Nelson et al., 2012) Another meta-analysis of 89 epidemiological studies conducted in 
2014 by Munsell et al. found that premenopausal obese women showed a 20% reduced 
risk of hormone receptor-positive BC when compared to underweight (summary RR, 
normal vs. obese or overweight 0.78, 95% CI, 0.67, 0.92). (Munsell et al., 2014) Adipose 
tissue is functionally a metabolically and hormonally active organ. Physiological 
variations between normal weight and overweight or obese premenopausal women 
related to BMI status may help to explain the weight-dependent variation in BC risk with 
regard to hormonal status 
 
2.3 Epigenetic Alterations in Breast Cancer 
 Though epidemiological studies have observed a significant negative correlation 
between obesity or overweight and BC risk in premenopausal women, the mechanism for 
this protective effect is yet unknown. One proposed mechanism for the reversible 
association between weight and BC risk found prior to menopause is the epigenetic 
modification of genomic DNA. BMI is known to elicit changes in the epigenome. (Meeks 
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2017) Further, BMI and menopausal status have been shown to co-vary with methylation 
patterns in BC. (Crujeiras et al., 2017) 
 
2.3.1 Gene-Specific Methylation, Obesity and Breast Cancer 
Changes in the methylation levels of the cytosines in cytosine-guanine 
dinucleotide-rich areas (CpG sites), of tumor supressor or DNA repair genes commonly 
induces genomic instability through gene transcription silencing. (Akhavan-Niaki & 
Samadani, 2013) These epigenetic alternations are early events in breast tumorigenesis. 
(Danforth, 2016) Abnormal hypermethylation of CpG sites in the promotor regions of 
tumor supressor genes is followed by loss of function, capable of increasing both somatic 
and germline mutations of genes in BC-related pathways. (Herman & Baylin, 2003)  
Several studies have investigated the relationship between body weight status and 
BC risk with regard to gene-specific DNA methylation levels. BMI is associated with 
aberrant promotor methylation levels of epiobesigenic genes governing cell growth, 
immune response, DNA repair and adipogenesis across many molecular subtypes of BC. 
(Holm et al., 2010) With regard to specific genes, RASSF1A, CCND2, ER-alpha and PR 
are reported to be hypermethylated in BC, as well as PTEN, CDKN1A and ESR1. (Y. T. 
Huang et al., 2016; Campion, 2009) In addition, BC-specific mortality has been found 
higher in obese women with promoter methylation in the APC gene (HR = 2.47; 95 % CI, 
1.43, 4.27). (McCullough et al., 2016) Table 1 includes a more extensive list of commonly 
reported genes with differential methylation in BC  
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Table 1. Genes differentially methylated in breast cancer. 
Function 
Gene 
Name 
Gene 
ID 
Biological Role Implicated in Cancer 
DNA Repair BRCA1 672 Tumor supressor 
  
BRCA2 675 Tumor supressor 
  
MGMT 4255 Defense against mutagenesis and toxicity 
  
MSH2 4436 Mismatch repair gene, DNA damage signaling 
  
MLH1 4292 Tumor supressor, DNA mismatch repair gene  
      
Cell-Cycle  SFRP1 6422 WNT inhibitor 
Regulation APC 324 Tumor supressor 
  
CCND2 894 Regulates G1-S (Cell growth to DNA replication phase)  
  
CDKN2A 
(P16) 
1029 Tumor supressor 
  
CDKN1A 1026 Regulates cell cycle progression at G1 
  
DAPK1 1612 Apoptosis, autophagy 
  
SCGB3A1 92304 Cell proliferation and differentiation 
      
ER+ vs ER- RASSF1A 11186 Tumor supressor, blocks cell cycle progression 
  
CCND2 894 Regulates G1-S phase 
  
ESR1 2099 hormone binding, DNA binding, transcription activation 
  
PGR 5241 Cellular proliferation and differentiation 
  
CDH13 1012 Tumor supressor. cell adhesion  
  
HSD17B4 3295 
Peroxisomal FA beta-oxidation pathway, differential 
methylation in HER2+ subtype 
  
BCL2 596 Inhibits apoptosis, Calcium signaling 
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With regard to methylation of genes in whole blood, the BC susceptibility genes 
BRCA1 and BRCA2 are two of the most frequently investigated. A recent meta-analysis 
of 40 studies supported the association between BRCA1 promotor hypermethylation in 
cancer versus non-cancer controls. (L. Zhang & Long, 2015) In contrast, in a healthy cohort 
of dominantly obese female nurses aged 40-60 years, obesity was not associated with 
BRCA1 or BRCA2 hypermethylation. (Peplonska et al., 2017) The relationship between 
methylation levels of BC susceptibility genes warrants further investigation. 
 
2.3.2 Global Methylation, Obesity and Breast Cancer 
In contrast to the hypermethylation of promotor regions of tumor suppressor genes, 
hypomethylation of non-coding genomic regions is characteristic of nearly all cancers, with 
BC as no exception. Global hypomethylation facilitates tumor promotion and progression 
through increased chromosomal instability. Results from studies on global methylation, 
body weight status and BC risk are varied, perhaps due in part to variations in inter-assay 
measurement validity. (Choi 2009, Cho 2010, Xu 2012) DNA methylation within specific 
regions of interest can be assessed with several different methods. Versions of High 
Performance Liquid Chromatography-based (HPLC) detection are considered the “gold 
standard” of global DNA methylation, but due to their considerable cost and need for 
special laboratory conditions, the use of HPLC for DNA methylation profiling is frequently 
less common. Two of the most popular substitutions for measuring whole-genome 
methylation profiles are long interspersed nuclear element-1 (LINE-1) and luminometric 
methylation assay (LUMA), as they exhibit higher specificity, sensitivity and lower assay-
to-assay variability than other methods of approach. Both methods require very little 
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genomic DNA and so are often used in conjunction, with LUMA serving as an internal 
control accounting for variability in the amount of DNA input. Of these two methods, 
LUMA and LINE-1, only LINE-1 assay data correlates well with HPLC-derived 
measurements, and LINE-1 is often recommended over the use of LUMA alone to assess 
whole genome methylation patterns. (Kurdyukov & Bullock, 2016) As more than one-third 
of methylation in the human genome is found in the CpG-rich sequences of Long 
Interspersed Nuclear Elements (LINEs), these transposable elements are considered a valid 
surrogate marker for global methylation. (Beck et al., 2011; Carraro et al., 2016; Irahara, 
Nosho, Baba, & Shima, 2010; Park et al., 2014) The largest subclass of these transposable 
nuclear elements is LINE-1. Hypomethylation of LINE-1 parallels global DNA 
hypomethylation and is characteristic of cancer cells. (Tang et al., 2016) 
Though evidence supporting blood-based DNA methylation as measured by LINE-
1 as a biomarker for BC risk is currently limited, a dose-dependent association between 
LINE-1 methylation from peripheral blood and BC risk has been reported. (Deroo et al., 
2014) The confounding effects of gender, age and lifestyle habits may explain the 
inconsistency in assessments between LINE-1 methylation and body weight status. 
Progressing age is associated with an increase in CpG island methylation but a decline in 
global methylation. (F. F. Zhang et al., 2011) LINE-1 methylation levels in white blood 
cells was negatively correlated with body fat mass but positively associated with a healthy 
lifestyle in a healthy, young cohort of men and women (mean age, 23 years; mean BMI = 
22kg/m2). (Marques-Rocha et al., 2016). Likewise, global methylation as measured LINE-
1 was positively associated with BMI in a recent cross-sectional study with a healthy cohort 
of postmenopausal women. (Boyne et al., 2017)  
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Due to its complexity and mutability, the quantification of CpG islands in repeating 
elements LINE-1 is not a perfect biomarker for global DNA methylation. Aside from the 
DeRoo study, most associations between global methylation and BC risk find significance 
only when assessing the data with quantile analysis. Of the thirteen studies assessed in a 
review by Tang et al. in 2016, the four study results with significant odds ratios (ORs) had 
used different methods of measuring DNA methylation. The two studies which used the 
LUMA assay found that women in the highest quantile of global methylation versus the 
lowest had higher risks of BC. In contrast, the other two studies with significant ORs had 
used LINE-1 and/or 5-mdC levels to measure methylation. 5-methyldeoxycytosine 
methylation is measured through liquid chromatography mass spectrometry. These studies 
both found a reduced risk of BC with higher DNA methylation levels, though the results 
from the two measuring methods did not correlate with each other. (Choi et al., 2009) 
Importantly, changes in genome-wide or gene-specific methylation patterns may be 
confined to the microenvironment of the breast tumor site and specificity has been shown 
to depend on the originating tissue. (Knothe et al., 2016) Previous studies on obesity, BC 
risk and survival rates and global methylation as measured by LINE-1 almost exclusively 
use DNA extracted from whole blood. (Tang et al., 2016) Samples for testing methylation 
levels extracted from the localized area of the breast as opposed to whole blood could 
reduce potential bias. As an example, in one of the few studies that show a positive 
relationship between BC risk, genomic hypomethylation and promoter hypermethylation, 
tumor and adjacent-tissue specific methylation levels of LINE-1 in invasive ductal 
carcinoma of the breast were found to be lower than in healthy tissue. In contrast, higher 
levels of promotor hypermethylation were exhibited in tumor and adjacent tissue, when 
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compared to methylation levels of whole blood cell DNA from the same subjects. (Cho et 
al., 2012) Studies assessing weight status, methylation patterns and BC risk using local 
tissue samples may provide a more accurate picture of early epigenetic changes in the 
obesity phenotype.  
In conclusion, though studies from the past five years may not show consistent 
associations between BMI and global DNA methylation (see review by Bell 2017), 
differing methods of measurement as well as originating tissue may be the significant 
contributors to this lack of consensus. Overall, gene-specific as well as sight-specific 
changes in methylation have been consistently observed in both case-control and larger 
intervention trials assessing BMI and BC risk. More studies addressing methylation, 
weight status and BC risk in premenopausal women specifically would need to be 
conducted to reach a consensus on these relationships.  
 
2.4 Folate Status and Breast Cancer 
Many of the critical cellular pathways disrupted in carcinogenesis are dependent on 
adequate folate status. Folate serves as the source of methyl groups for de novo nucleotide 
synthesis, DNA repair and the maintenance of the epigenetic landscape. Methyl donor 
depletion, as in a state of folate deficiency from inappropriate nutrition, significantly 
disrupts all areas of one-carbon metabolism. (Friso, Udali, De Santis, & Choi, 2017)  
The anti-cancer effects of foods high in folate have been studied for many decades. 
Dietary folate intake is essential to proper nucleotide synthesis, DNA repair and 
methylation, all of which are disrupted in carcinogenesis, and adequate folate status 
exhibits a protective effect against risk of many cancers. (Kim 1999) Diets low in fruits 
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and vegetables often lead to diminished folate status. Overall vegetable intake has been 
associated with lowered premenopausal BC risk, though it is speculated that many 
compounds within the food (folate, fiber, phytochemicals, etc.) have a synergistic effect on 
risk reduction. (Freudenheim et al., 1996) More recently, cruciferous vegetable intake, a 
class of vegetables that are high in folate, has been associated with a decreased risk of 
premenopausal BC in a Japanese cohort. [multivariable RR for intake, highest vs. lowest = 
0.64 (95 % CI, 0.38-1.10; p for trend = .046)]. (Suzuki et al., 2013) Furthermore, some 
evidence suggests that an adolescent diet low in green leafy and cruciferous vegetables 
may influence premenopausal BC incidence. (Harris, Willett, Vaidya, & Michels, 2017)  
Several studies, including meta-analyses, have been conducted assessing the 
association between BC risk or BC-specific mortality and folate. Akin to the effect of 
certain food groups on premenopausal BC, epidemiological studies have shown mixed 
results as to folate’s explicit role in associated BC risk. (See Table 2.)  
Dietary folate (DF) status and total folate (TF, both dietary and from all sources) 
status, as measured through food frequency questionnaires (FFQs), are the most widely 
used exposures. Dietary folate status, when compared by lowest and highest intake, has not 
been associated with a higher RR of BC for both metastatic and invasive carcinoma in most 
meta-analyses. (Rohan et al., 2000, Cho 2003, Kabat et al., 2008, Bassett et al., 2013) This 
finding has remained true for larger-scale prospective cohorts, such as in the Canadian 
National Breast Screening Study (CNBSS) and Melbourne Collaborative Cohort Study 
(MCCS).  
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Table 2. Prospective studies and results on the association between dietary or total folate intake and breast cancer risk by 
premenopausal status.  
Authors 
Study 
Period 
N BC† 
TF or 
DF‡ 
Age Study Cohort P for trend Conclusions 
Zhang et 
al., 1999 
1980-
1996 
88,818 3483 TF 30-55 
Nurses' Health 
Study 
0.98 
 
No association. 
 
Rohan et 
al., 2000 
1980-
1993 
5,382 1,336 DF 40-59 
Canadian 
National Breast 
Screening Study 
0.32 
 
No association for DF. Suggestion of 
increased risk at highest quintile of 
DF in premenopausal women; 95% 
CI included unity. 
Cho et al., 
2003 
1991-
1999 
90,655 714 both 26-46 
Nurses' Health 
Study 2 
TF 0.96 
DF 0.94 
 
No association. 
 
Zhang et 
al., 2005 
1980-
2000 
88,744 4,422 both 30-55 
Nurses' Health 
Study 
0.03 
 
Higher TF intake associated with 
reduced RR of ER- but not ER+. 
ER+ associated with increased risk.  
 
Cho et al., 
2007 
1991-
2003 
90,663 1,032 both 36 14 States (US) 
TF 0.31 
DF 0.77 
 
No association (BC overall or ER- 
breast cancer).  
 
Larsson et 
al., 2008 
1990-
2001 
61,433 2,952 TF 53.3 
Swedish 
Mammography 
Cohort 
TF 0.84 
ER+/PR- 0.01 
 
No association for BC overall. 
Suggestion of inverse association 
with ER+/PR- tumors.  
 
Kabat et 
al., 2008 
1980-
2000 
49,654 2,491 DF 40-59 
Canadian 
National Breast 
Screening Study 
0.79 
 
No association. 
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Shrubsole 
et al., 
2011  
1997-
2008 
72,861 718 DF 40-70  Shanghai, China 0.032 
 
Higher dietary folate intake 
associated with a 40% decreased 
BC risk for high vs. low intake. 
 
Bassett et 
al., 2013 
2010 20,756 936 DF 41-86 
Melbourne 
Collaborative 
Cohort Study 
>0.07 
 
No association. 
 
† Breast cancer cases; ‡ total folate or dietary folate; N,  number of study participants; BC, breast cancer; age, age at baseline; RR, relative risk; 95% CI ,95% 
confidence interval; ER+, ER-, Estrogen receptor positive, estrogen receptor negative; PR+, PR- Progesterone receptor positive, progesterone receptor 
negative. 
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In contrast, a meta-analysis of five studies assessing folate intake before diagnosis 
of BC by Li et al. reported a significant inverse relationship between DF intake and all-
cause mortality (highest vs. lowest; pooled HR from all five studies 0.74, 95% CI, 0.60-
0.92). (Li, Lu, Wang, & Zhang, 2015) All-cause mortality in BC patients was significantly 
lower in the highest levels of folate intake, showing a 14% risk reduction compared to 
lowest. Using two of the studies included in this meta-analysis, Sellers 2002 and Harris 
2012, the authors also found a dose-response relationship between dietary folate intake at 
increments of200g/day and all-cause mortality (summary HR 0.86; 95% CI, 0.76-0.97). 
(Li et al., 2015) However, no association was found between total folate intake and BC 
risk.  
In a meta-analysis of 14 cohorts from 19 studies (n=677,858), a non-linear 
relationship was observed between folate intake as measured by FFQ and BC risk (p-value 
for non-linearity = 0.0007). (F. Zhang et al., 2014) Zhang et al found that 200-320g/d of 
dietary folate was associated with a lowered risk of BC, verses a significant increase in risk 
with daily folate intakes above 400g. Intake at these levels (200-320g/d) though below 
the RDA of 400g/day, are often the median of intake in prospective studies on folate 
intake and BC risk. Similarly, a meta-analysis by Chen et al. in 2014 investigated the effects 
of folate on BC risk. After correcting for publication bias, statistical methods using models 
that assume linearity yielded different results than models that assumed non-linearity. In 
the 16 prospective studies, no linear association was found between DF and BC risk 
[pooled RR=1.04 (95% CI, 0.94,1.15)]. In contrast, women with DF intake between 153-
400µg exhibited a reduced risk of BC compared to those whom consumed <153g of folate 
daily, while women with average DF intakes above 400g did not see this reduction in 
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risk. In the 25 case-control studies, a significant negative correlation was reported between 
BC risk and DF intake, though this result was not linear [pooled OR under linear model = 
0.99 (95% CI, 0.84 -1.16)]. BC risk reduction was significant for women with higher DF 
intake compared with those with DF intake <130.5 g per day, where a 100 μg per day 
increase of DF was associated with a 9% reduction in BC risk (OR = 0.91; 95% CI, 0.86–
0.97) 
Of consideration, results from the Chen et al. paper suggest higher folate intake is linearly 
associated with BC risk reduction in non-US populations, but not in American cohorts. 
This may be due to difference in folic acid fortification levels of the food supply; 
populations with relatively high folate status may confer a weaker protective effect. When 
stratified by menopausal status, DF was not associated with BC risk [highest vs. lowest 
category of intake, fixed- or random-effects model and 95% CIs, respectively:  1.05 (0.86–
1.28), 1.02 (0.62–1.67)], though only 20 of the 42 included studies reported data on 
menopausal status. 
A seminal prospective cohort study conducted in 1999 of more than 88,000 women 
(3483 cases of invasive BC) found total folate was not associated with an overall reduced 
risk of BC. Despite this, the excess risk of BC associated with 15g of alcohol intake per 
day was reduced by total folate intake. Folate intake above 600g/d had a 7% decrease in 
risk compared to participants with intake between 150-299g/d [multivariate relative risk 
(RR) of 0.55 (95% CI, 0.39-0.76; p for trend = .001)] This association was only slightly 
attenuated after additional adjustment for intake of beta carotene, lutein/zeaxanthin, 
preformed vitamin A, and total vitamins C and E. (S. Zhang et al., 1999) 
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There is limited evidence on hormone receptor-specific premenopausal BC risk and 
dietary folate intake. In a prospective study on a subset of the European Prospective 
Investigation into Cancer and Nutrition (EPIC) cohort (n=367,993 women), researchers 
found that higher DF intake may be associated with reduced risk of hormone-receptor-
negative BC in premenopausal women. A statistically significant trend towards lower risk 
in estrogen receptor-negative BC (HR, highest vs. lowest = 0.66; 95% CI, 0.45-0.96, p for 
trend = .042) and progesterone receptor-negative BC (HR, highest vs. lowest = 0.70; 95% 
CI, 0.51-0.97, p for trend = .021) was exhibited. (Batlle et al., 2014) 
In another cohort study with 3,016 overweight and obese women, a marginal 
inverse association between dietary folate intake and premenopausal status was found in 
African American women who consumed more than 230mcg/d of natural food folate but 
did not reach significance (highest vs. lowest quartile: OR=0.57, 95% CI, 0.33–1.00; p for 
trend = .06). After stratification by hormone receptor status, this association between 
premenopausal BC risk and folate status was further diminished. In their conclusion, the 
authors of this study suggested other B vitamins may modify the relationship between 
folate and premenopausal BC risk, as the lowest ORs were observed in women who 
consumed the highest levels of natural food folate as well as either B12 or methionine (OR 
= 0.60, 95% CI, 0.37–0.96 and OR = 0.42, 95% CI, 0.25–0.72, respectively). (Gong 2014)  
Previous epidemiological studies investigating folate intake and their non-
consensus among results may be due to differences in methods of folate status assessment 
(self-reported versus validated food frequency questionnaire) or due to the timing of 
measurement (pre- or post-BC diagnosis). Reported folate intake and relative status may 
differ; misclassification due to self-reported low intake may offer a causal explanation as 
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to why folate intakes at levels below the RDA are not associated with risk reduction. It is 
known that dietary assessments using self-reported intakes can exhibit systematic bias, 
especially with regard to energy underreporting in a female cohort. Therefore, it is 
suggested that self-reported intakes are used in conjunction with biomarkers for folate 
status such as serum or red blood cell (RBC) folate, especially when considering intakes at 
levels indicative of folate deficiency or excess. (Bailey et al., 2017) 
It is important to note that higher folate levels, such as those reached with intakes 
of supplements or fortified foods, are more closely correlated with folate levels as assessed 
with self-reporting and validated with biomarkers. Systematic underreporting is prominent 
in epidemiological studies, which assess folate status by food frequency questionnaire or 
through 24-hour recall. This is of special concern with regard to studies investigating all-
female cohorts, as women tend to systematically underreport energy intake more often than 
men. Caution is recommended when interpreting the relationship between health outcomes 
and lower folate intakes when measured by self-reported data. (Bailey et al., 2017) A 
further consideration: though self-reported dietary data in large epidemiological studies 
can be paired with biomarkers to increase the strength of observed folate status and health 
outcome associations, both serum and RBC folate are not true recovery biomarkers. Folate 
levels as assessed by these measures still cannot correct for the systematic bias of energy 
underreporting that is common to dietary assessments using FFQ. 
Folate status and its role in BC etiology may also depend as heavily on timing of 
intake as well as relative intake levels, especially with regard to risk in premenopausal 
versus postmenopausal BC instance.  Dietary intake pattern changes between pre- and post-
diagnosis have been reported in up to 30-40% of participants in some epidemiological 
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studies on BC risk. (Salminen et al., 2000 and Maunsell et al., 2002) The authors suggested 
their findings support adequate folate intake pre-diagnosis, as opposed to supplementation 
with high doses post-diagnosis.  
At present, study findings have suggested a U-shaped curve relationship between 
individual vitamin intakes and health risks, including folate. (Chen et al., 2014) Following 
a sharp observable increase in colorectal cancer after food fortification with B vitamins, 
early studies were held to investigate the relationship between increased folate intakes due 
to food fortification and various health outcomes. (Selhub & Rosenberg, 2016) The 
American Institute of Cancer Research (AICR) and World Cancer Research Foundation 
(WCRF) both advise meeting vitamin and mineral needs through dietary rather than 
supplemental sources, in order to keep intake below levels that may pose risk (WCRF and 
AICR, 2007).  
Like studies using FFQs, results compared with circulating plasma or RBC folate 
levels as indicators of status are also disagreement with regard to folate’s impact on BC. 
Serum and RBC folate are the two commonly used biomarkers to assess folate status. 
Where RBC folate levels correlate with tissue folate levels and are a more reliable measure 
of long term folate status, serum folate is subject to transient changes in dietary folate 
intake, and is therefore a poorer indicator of long term status. This lack of consensus with 
biomarker data may be due to fewer numbers of studies overall or due to differences in 
both lifestyle-related exposures (such as alcohol intake, a known folate disruptor, or 
smoking) and genetic predispositions in their cohorts. Further, few analyses on serum or 
RBC folate and BC have reported results with regard to both BMI and premenopausal 
status, specifically.  
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In a meta-analysis of twelve studies on BC risk and serum or RBC folate status by 
Lin et al. in 2008, no associations between folate biomarkers (serum or RBC) and BC risk 
reached statistical significance for ten of the studies, and only one study reported their 
findings with regard to menopausal status. (Lin et al., 2008).  
In one of the studies that reached statistical significance in the Lin et al. meta-analysis, 
serum folate levels were assessed for carriers of the methyltetrahydrofolate reductase gene 
(MTHFR>C677T, wildtype or single nucleotide polymorphism) and compared to risk of 
BC instance. In the 141 BC patients and 109 age-matched controls, increased serum folate 
levels were significantly associated with a reduced risk of BC (quartiles, g/L; p for trend 
= .001), but these results were not adjusted for menopausal status. (Beilby et al., 2004) In 
a later publication from this lab, using a sub-cohort within a larger prospective study in 
Caucasian West Australians, RBC folate but not serum folate was inversely associated with 
BC risk [n=569 women without cancer at first interview; adjusted HR per decrease of 
100g/L 1.96 (95% CI, 1.22, 3.12); p for trend < .01]. (Rossi et al., 2006). The trend for 
serum folate was similar but did not reach significance (p = 0.17). Participants in the lowest 
folate category (<200g/L) had an adjusted HR of 6.46 (95% CI, 1.19, 35.07) for a 
subsequent cancer event. With a total of only 19 BC events in this sub-cohort, statistical 
power to assess the relation between folate levels and site-specific cancer instance was 
greatly diminished, compared to the original cohort, and caution should be exercised when 
interpreting the results of this study.  
In the remaining study which reached significance within the Li et al. meta-
analysis, a nested case control using the Women’s Health Study cohort, plasma folate levels 
were positively associated with premenopausal BC but not postmenopausal BC [RR 1.42 
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(95% CI, 1.00, 2.02) for plasma folate, p for trend = .04 (adj. for BMI)]. (Lin et al., 2008) 
As described by authors of this study, additional research is needed for to explore these 
unexpected results.  
In conclusion, though studies from the past five years may not show consistent 
associations between folate status and the risk of BC, different methods of folate status 
assessment, menopausal status, and obese state may be the significant contributors to this 
lack of consensus. In FFQ results, most studies do not describe a significant pattern. Results 
using biomarkers of folate status are mixed, as well. Going further, studies must account 
for menopausal status as well as bodyweight in order to delineate how these factors interact 
to influence the development of BC or BC-related mortality. 
 
2.5 Folate and Methylation 
Folate serves as both donor and acceptor of methyl groups in many one-carbon 
metabolism reactions, including DNA methylation. As a one-carbon donor deficiency will 
alter the rate of DNA methylation, fluctuations in folate levels disturb the maintenance of 
DNA methylation following replication. The deleterious effects of low folate on DNA 
methylation have been observed in numerous cancer cell models, though the effect and 
rage of impact of this depletion varies among cancer cell type. (Jin et al., 2009) 
Indeed, in vitro studies have shown folic acid elicits changes in both the transcriptome and 
methylome of BC lines, though findings supporting the latter are varied. In an in vitro study 
by Price et al. using 1mg/d of folic acid supplementation, levels of folic acid in excess of 
normal recommended dietary intake levels (1mg/d versus the RDA of 400g/d and 
800g/d for women of child-bearing age), on both normal and BC cell lines showed no 
variation between methylation of CpG sites on two breast-cancer related genes, BRCA1 
 24 
and BRCA2. (Price, Lillycrop, & Burdge, 2015) In a more recent cell culture study by the 
same authors on both non-transformed and cancerous BC models, physiological 
concentrations of folic acid (100nm/l of folic acid) were shown to affect regulation of genes 
associated with apoptosis, senescence and cell proliferation. (Price 2016). Again, no affect 
was found on BRCA1 or BRCA2 DNA methylation by breast cell line in this study.   
 
2.6 Obesity, Folate Status, Methylation and Cancer 
Folate serves as a methyl donor for adequate DNA methylation and folate levels 
are sensitive to weight status. Epigenetic responses to folate status have been shown to be 
bodyweight dependent. DNA methylation patterns differ between metabolic states, and 
fluctuations throughout the lifespan of both folate status and BMI elicit modifiable changes 
in the epigenome. (Meeks et al., 2017)   
Both folate levels and distribution can vary by bodyweight. In a study by Tinker et. 
al., BMI was inversely associated with serum folate concentrations. (Tinker et al., 2012) 
Using NHANES data, Bird et al. found that young overweight and obese women had lower 
serum folate and higher RBC folate levels when compared to either men or older women 
of the same weight categories. (Bird et al., 2015) Even after adjustment for intake, BMI 
has been shown to affect the distribution of folate from circulation into tissue. (da Silva et 
al., 2013) This redistribution may affect the availability of folate as a substrate for global 
and gene-specific methylation.  
Though many of the exact mechanisms underlying these associations have yet to 
be discovered, DNA methylation patterns in premenopausal overweight or obese women 
with BC are often significantly different from postmenopausal women with BC. Whether 
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changes in DNA methylation in response to folate levels and bodyweight are deleterious 
or protective against risk may heavily depend on menopausal status or age.  
Differences between serum and RBC folate concentrations as well as epigenetic 
responses to folate interventions provide evidence in support of the significant effect of 
menopausal status and cancer risk. Many of the existing studies on folate status, 
bodyweight and premenopausal women have focused on the effects of folic acid 
supplementation against baseline serum or RBC folate levels. Within women of child-
bearing age, folic acid supplementation has been shown to elicit different effects on 
methylation levels of folate metabolism-associated genes, dependent on weight status. 
Response to folic acid supplementation has been shown to be lower in healthy obese 
compared to healthy normal weight premenopausal women. (Da Silva et al., 2013) In obese 
women both before and after intervention with supplementation, open seas CpG sites of 
cancer-related genes in obese women were more likely to have higher degrees of change 
in response to folic acid supplementation, despite overall lower levels of serum folate. 
(Yong‐Moon et al., 2017) 
Results from the few investigations on BMI, folate, methylation, menopausal status 
and differences in BC risk have been mixed. A possible explanation for these mixed results 
is that the relationship between these factors may be contingent on age, area of fat 
disposition, and metabolic activity of adipose. Localized inflammation often precedes the 
development of BC, and obesity-related low-grade inflammation increases with age. 
(Frasca, 2017) A state of subclinical inflammation has been documented in the breast 
adipose of healthy, postmenopausal women with normal BMI as opposed to 
premenopausal women. It is speculated that obesity-associated metabolic or inflammatory 
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effects, such as increased Cytochrome P450 expression, may alter serum folate oxidation 
products and degradation rates, leading to changes in DNA methylation. (De la Rocha et 
al., 2016) Thus, age may play an inflammation-associated role in weight and methylation-
related BC risk 
Changes in epigenomic patterns are tissue-specific. Consequently, the method of 
folate assessment may also play a role in the varying results from the few investigations on 
BMI, folate, methylation, menopausal status and differences in BC risk. DNA methylation 
is highly associated with BMI when measured in adipose tissue, as opposed to blood, 
though the methylation patterns of women with a high BMI are more similar to patterns 
measured in peripheral tissues such as blood. (T. Huang et al., 2016) Results from studies 
assessing folate status and DNA methylation by bodyweight may be affected by 
measurement assessments; serum, RBC or whole blood DNA methylation profiles may 
show lower correlation with bodyweight status versus tissue-specific measurements of 
folate and DNA methylation patterns.   
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CHAPTER 3  
HYPOTHESIS AND SPECIFIC AIMS 
 
Obesity has increased with an alarming rate in the United States, and a further increase, 
from the current 1/3 of the US population to ~50% by 2030, is projected. Mounting 
epidemiological evidence suggests that overweight and obesity is a robust risk factor of 
many types of cancers. However, the connection between overweight and obesity and 
breast cancer is complex – a well-established positive association exists between obesity 
and postmenopausal BC, whereas a reverse association holds prior to menopause. A 
significant challenge for understanding the cellular and molecular mechanisms of action 
by body fatness is the apparent enhancement of risk for postmenopausal BC but a 
protective impact for premenopausal BC. A great number of studies have been conducted 
to understand the positive association between obesity and postmenopausal BC, and 
several mechanisms governing this association have been proposed and defined, including 
adipose tissue-driving circulating hormones (e.g. IGF-1, estrogens) and obesity-associated 
chronic low-grade inflammatory state. On the contrast, mechanistic studies to understand 
the negative association between obesity and premenopausal BC is extremely limited, and 
the pathways that inform this inverse relationship remain entirely un-delineated. 
 
A recent publication from our laboratory using the National Health and Nutrition 
Examination Survey (NHANES) dataset demonstrated that despite lower dietary intake, 
overweight and obesity is associated with increased levels of RBC folate. This association 
particularly holds to be significant for premenopausal women. Based on this surprising 
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observation, we conceived our hypothesis: obesity exerts its protective impact on 
premenopausal BC via altering folate metabolism and DNA methylation. To elucidate this 
potential mechanism, we propose the following specific aims: 
 Specific Aim #1: to determine to what extent obesity affects folate status in mammary 
tissue from cancer-free premenopausal women.  
Specific Aim #2: to determine how obesity, via altering folate metabolism, influences 
mammary genome-wide and gene-specific methylation.  
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CHAPTER 4 
METHODS 
 
4.1 Participants 
Histologically normal breast biopsy samples were collected from 51 premenopausal 
women who underwent elective mastectomies at Baystate Medical Center in Springfield, 
Massachusetts. Data on parity, age and BMI status was included. Participants signed an 
authorization for release of medical information upon donation of tissue samples. Samples 
were stored in -80C until use. 
 
4.2 Assays 
 
4.2.1 Lactobacillus casei Microbiological Folate Assay 
The Lactobacillus casei microbiological assay is considered the gold standard of 
folate assessment today due to its affordability, sensitivity and ability to detect various 
conjugate forms of folate that are representative of folates naturally occurring in biological 
samples. Folate is essential for growth in L. casei (formally known as L. rhamnosus. so as 
such, relative concentrations of folate from tissue or serum samples available for microbial 
uptake can be estimated by comparison to the amount uptake of a known concentration of 
folic acid. The limit of detection (LOD) for folate forms using the L. casei assay is very 
low (>50 picomoles), making it suitable to detect relatively small concentrations of total 
folate, such as concentrations from breast tissue biopsy samples.  
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4.2.2 Generation of the Folic Acid Standard and Standard Curve 
A known concentration of folic acid (10 mg/mL; Sigma F-7876) is dissolved into 
doubly-distilled H20 and titrated with 0.1M NaOH until visibly clear. Folic assay standard 
stock is stored in a dilution of 1:20 of methanol, aliquoted in microcentrifuge tubes and 
wrapped in foil to prevent light degradation. Standard stock is prepared once, stored in -
80C and used within one month.  
L. casei suspension consists of 10 L of cryoprotected L. casei (Difco Lactobacilli 
Broth AOCA, Cat. 290100) and 150 L of growth medium. 150 L of L. casei suspension 
and 150 L of potassium phosphate buffer (KPO4) are added to all wells of a 96-plate. A 
concentration of 6 ng/mL folic acid is added to the bottommost row and serially diluted up 
the columns, leaving the topmost row blank (concentrations of folic acid: 6 ng/mL to 0 
ng/mL). Folic acid standard suspensions are run in multiple replicates (octuplet) on a 96-
well plate to control for intra-assay variation with three wells of 300 L KPO4 buffer 
serving as internal control for inter-assay variation. All plates for the folic acid standard 
will be run on the same day.  
The relative turbidity of each well is caused by the extent of microbial growth, and 
consequently, indicative of available folates. Turbidity of samples can be measured by 
optical density (absorbance) on a spectrophotometer at the wavelength of 630 nanometers 
(nm). Concentration (g/l) of folic acid is then calculated with the following formula: 
molarity determined by optical density divided by molecular extinction coefficient for folic 
acid (=9260). Molarity is then multiplied by molecular weight for folate (441.4 g/mol) to 
determine concentration (g/l). As L. casei growth exhibits saturation kinetics and is 
repressed by excess folate, the standard curve is generated by log-transforming the growth 
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response rates of folic acid to L. casei. The generated standard folate growth curve must 
be log-transformed to accurately compare the unknown relative folate concentrations in the 
breast tissue samples to the known concentrations. 
 
 
4.2.3 Breast Tissue Extraction and Folate Assay 
Breast tissue samples are quickly weighed while still frozen, added to extraction 
buffer and homogenized. Samples are then boiled for 20 minutes, treated with rat plasma 
conjugase and incubated for 2 hours. After folate extraction, breast tissue samples are 
stored at -80C until L. casei microbial assay is performed. 
All microbiological folic assay reagents are prepared fresh on the day of assessment 
with ascorbic acid added to further prevent oxidation and degradation due to storage and 
light exposure. On the day of microbial folate assay with breast tissue samples, one aliquot 
of folic acid standard stock is diluted for use in KPO4. A serial dilution of the folic acid 
standard at a concentration is then performed in the first 2 columns of a 96-well plate. 
10 L of cryoprotected L. casei (Difco Lactobacilli Broth AOCA, Cat. 290100) is 
suspended in freshly prepared L. casei media and added to each remaining well of a 96-
well plate (L. casei suspension total volume, 150 L). Each breast tissue folate extraction 
sample is run in triplicate to reduce intra-assay variation. All plates are ran within one 
week, with 3 wells of L. casei suspension, human plasma and KPO4 buffer serving as the 
internal control. The prepared 96-well plates are mylar sealed and incubated overnight in 
a dry incubator at 37C (18h) to be read on the spectrometer on the following day. 
Total folate concentration is determined for each sample by photospectometry at 
630 nm. Mean tissue folate concentrations for each sample will be calculated as the 
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weighted average of measurements ran in triplicate using the coefficient of variation 
between triplicates. Mean tissue folate concentration is determined by comparison to the 
known concentration of serially diluted folic acid standard.  
 
4.3 DNA Extraction and Gene Expression  
DNA is extracted from DNEasy kit (Qiagen). DNA concentrations and absorbance 
(260/280nm ratio) is quantified by Nanodrop spectrophotometer. Nineteen BC-related 
genes with aberrant epigenetic modifications were identified in existing literature. RT-PCR 
amplification will be performed to compare relative gene expression between BMI groups. 
Validated PCR primers for each gene were selected by a scan of the existing literature. RT-
PCR will be performed on 96-well plates with the ViiA 7TM Real-Time PCR (Life 
Technologies) and analyzed with accompanying software (Expression Suite).  
 
4.4 Pyrosequencing for DNA Methylation  
The average amount of both loci-specific and global DNA methylation analysis is 
conducted via targeted Next Generation Bisulfite Sequencing (pyrosequencing) by 
EpigenDX (Hopkinton, MA); where LINE-1 and Alu elements serve as the surrogates for 
global DNA methylation. EpigenDX’s pyrosequencing methods include multiple quality 
control checkpoints, including bias testing for PCR conditions such as annealing 
temperature (ensuring nonbiased selection between methylated vs. unmethylated CpG 
sites) and sensitivity analysis. After Pyrosequencing analysis and data compilation, 
delivered results include both quantitative Pyrosequencing values (percentage methylation 
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values of each CpG site, provided in Excel) and raw Pyrogram data (provided in Microsoft 
Word). 
4.5 Statistical analysis  
Data are expressed as means ± SEM, and statistical analysis was performed using 
SAS (Version 9.4, SAS Institute, Cary, NC). Because the population of women undergoing 
reduction mammoplasty typically had high BMIs, we combined the normal (BMIs between 
18-24.9 kg/m2) and the overweight (BMIs between 25-29.9 kg/m2) women together and 
grouped subjects into two categories; non-obese group with a BMI < 30 kg/m2 and obese 
group with BMI ≥ 30 kg/m2. To compare differences between these 2 groups, a T-test was 
used, and also when a multiple comparison was performed, significance was accepted with 
p < 0.05 and a FDR cutoff of q < 0.25.  For the association analysis, Pearson correlation 
analysis was performed for the association between BMI and mammary tissue folate, BC 
related gene expression and genome-wide DNA methylation and gene-specific 
methylation. 
For gene expression, each gene was normalized to the housekeeping gene GAPDH 
(Ct = Cttarget gene-CtGAPDH). Statistical analyses were performed based on differences in 
ΔCt between non-obese individuals with BMI < 30kg/m2 and obese individuals with BMI 
≥ 30 kg/m2 and relative expression is reported as 2−ΔΔCt, where ΔΔCt=CtBMI≥30-CtBMI<30.   
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CHAPTER 5 
RESULTS 
 
5.1 Participants 
Anthropometric characteristics of study participants are shown in Table 3. 
Participants were characterized into BMI classes, Normal Weight, Overweight and Obesity 
based on the principal cut-off points established by the World Health Organization 
standards for BMI categorization (WHO).  Mean BMI for the <30 kg/m2 group was 26 
kg/m2 (n=27). Mean BMI for the >30 kg/m2 group was 35 kg/m2 (n=23). There were no 
significant differences among the different BMI categories with regard to parity or age (p 
> 0.05). When compared to the Normal Weight group, age was marginally higher (p = 
0.092).  No others significant differences were measured.  
 
Table 3. Anthropometric Characteristics of subjects. 
 
*Different letters denote significant differences among the BMI categories ( p < 0.001). 
There are no significant differences of numbers of parous women and age among the 
different BMI categories ( p > 0.05), with a marginal higher age for the Obesity group when 
compared to the Normal Weight group (p = 0.092).  
 
 
5.2 Obesity and Mammary Tissue Folate Status  
The folic acid concentration standard curve was generated using a known concentration of 
folic acid. An example of plate layout is included in Figure 1. Tissue folate samples were 
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run in triplicate, KmNO4 buffer was used as an internal control and human plasma as a 
control for inter-assay variability.  
 
 
Figure 1.  Lactobacillus casei folic acid assay standard plate layout 
 
Mean tissue-specific folate for all groups was 17.042 kg/m2. Mean tissue-specific 
folate level is significantly higher in obese versus non-obese women (<30 BMI 15.31, >30 
BMI 19.59, p = 0.0439). (Figure 2) Breast tissue folate level in obese women (19.59 ng/g) 
is 28% higher (p  < 0.05) when compared to folate status in non-obese women (15.31 ng/g). 
No statistically significant difference was found between normal and overweight BMI and 
tissue folate.  
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Figure 2. Association between tissue folate and BMI. 
* denotes statistical significance (p <0.05). 
 
A significant positive correlation (p < 0.01) was observed between breast tissue 
folate status and BMI (Figure 3). A high BMI is associated with increased folate levels in 
mammary tissue, with an increase of 2.65 ng/g of folate per every 5-unit increase of BMI 
(p-value for slope = 0.0064). 
 
.  
Figure 3. Linear association between BMI and tissue folate. 
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5.3 Global DNA Methylation  
LINE-1 methylation was measured as a surrogate of global DNA methylation. 
LINE-1 methylation is significantly associated with BMI (p < 0.05). (Figure 5) The normal 
weight group was not significantly different from overweight or obese, and overweight and 
obese were not statistically different from each other. For global methylation as measured 
by 4 CpG sites along LINE-1 elements, BMI both overweight and obese groups showed 
higher percent LINE-1 methylation than the obese group (p < 0.05). The difference 
between overweight and obese was not significant. (Figure 4) LINE-1 methylation is also 
marginally associated with mammary tissue folate levels, but this association did not reach 
significance (p = 0.087, data not included).  LINE-1 Methylation and BMI share a positive 
linear association. A 0.014% increase in LINE-1 methylation per unit of BMI was observed 
(p for trend = .034). (Figure 5) 
 
Figure 4. BMI status and percent LINE-1 methylation. Letters denote statistical 
significance between BMI categories (p < 0.05). 
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Figure 5. Linear correlation between BMI and percent LINE-1 methylation.  
 
 
5.4 Gene Expression  
Out of the eighteen genes selected from the literature for analysis via RT-PCR, only two 
provided significant results. Relative expression levels of SFRP1 correlated with BMI 
status. The SFRP1 gene codes for WNT pathway antagonist protein with tumor suppressor 
function. SFRP1 is downregulated in 46% of breast cancers. SFRP1 gene expression levels 
positively correlated with both BMI (p = 0.0105) and tissue folate (p = 0.0313). (Figure 6) 
BMI and SFRP1 gene expression also shared a positive linear correlation, with an increase 
of 0.112 relative fold for each unit of BMI (p for trend = 0.023, Figure 7). 
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Figure 6. Relative gene expression of SFRP1. * denotes statistical significance (p < 
0.01), ** denotes statistical significance (p < 0.001). 
 
 
 
Figure 7. BMI and relative gene expression of SFRP1. SFRP1 gene expression levels 
positively correlated with BMI (P for correlation = 0.023). 
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5.5 Gene-Specific DNA Methylation  
SFRP1 was selected for promotor CpG site methylation analysis based on its 
significant correlations with regard to gene expression, BMI, and folate status. For the 8 
CpG sites analyzed in the promoter region of the SFRP1 gene, no associations were 
observed for both BMI and tissue folate (p > 0.05), although a high expression was 
observed in the subjects with high BMI or high tissue folate (p  < 0.05). 
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CHAPTER 6 
DISCUSSION 
 
6.1 Strengths and Limitations  
One strength of our study is the reliability of our results, due to the laboratory assays 
we elected to employ. We assessed global and gene-specific methylation levels using tissue 
samples from the breast, rather than whole blood. As our study was concerned with the 
localized environment of the healthy breast, and DNA methylation levels are known to 
vary by originating tissue, assessing the degree of methylation in mammary as opposed to 
peripheral tissue may better reflect the status of the healthy breast microenvironment. 
Further, our samples contained a heterogeneous selection of cell types, in that they 
contained adipose, epithelial and structural tissue. DNA methylation of adipose tissue is 
highly correlated with BMI, especially in individuals with a high BMI. (Huang 2016) With 
regard to folate status, biologically relevant tissue folate levels typically fall well above the 
limit of detection (LoD) for the L. casei assay. Biological concentrations of folate are 
generally in the nanograms per liter range, as opposed to nanomoles per liter (the assay’s 
LoD). As such, our findings may accurately denote biological relevance despite the f fact 
that the quantification of tissue folate levels were relative to our folic acid standard rather 
than absolute values. The lowest measured point on our folic assay standard calibration 
curve was greater than 6 nmol/L, well above the limit of detection for the L. casei assay. 
Additionally, both our standard curve for folate growth and calculated results for 
sample levels agreed with values previously reported by other laboratories. As the assay is 
very sensitive, measures were taken to reduce variability. Two internal controls were used, 
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human plasma and KPO4 buffer, and all reagents for the assay plates were generated on 
the same day by the same researcher (or used within less than one week). All plates were 
generated and analyzed by the same researcher, which reduced the likelihood of variability 
due to inconsistencies between technicians. In conclusion, not only are our L. casei assay 
results in agreement with typical concentrations in the previous literature, our study design 
may more accurately reflect the molecular and epigenetic heterogeneity that is present 
within the human breast  
Another strength is the potentiality for method agreement between this 
investigation and large epidemiological studies. Despite the invention of protein-based 
assays to detect folate concentrations, the L. casei microbiological assay is still the most 
highly recommended assay to determine folate concentrations in biological samples. Thus, 
it is widely used in prospective cohorts. For example, NHANES is one of the largest and 
most detailed cohort studies in the United States. NHANES collects data on a wide range 
of variables beyond biospecimens related to micronutrient status, including lifestyle habits, 
environmental exposures, occupation, reproductive health. Many of such variables have 
been previously shown to be associated with BC risk. Though NHANES methodology 
briefly switched to protein-based assays for folate status assessment in the 2000s, it 
reverted back to the L. casei assay in subsequent years. Since we employed the same 
method of folate assessment, our results may be more readily compared against their 
outcomes.  
Our study has several limitations. Tissue samples were donated from local women 
who underwent elective mammoplasty, and the accompanying data concerning the 
subjects’ characteristics was limited to BMI category, menopausal status, age and parity. 
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Beyond these parameters and the classification as “healthy” women, we were unable to 
distinguish whether there were any pre-existing conditions that would influence their 
decisions to receive a breast reduction or speak to their underlying metabolic health. There 
are many factors beyond aesthetics that may influence a woman’s decision to have breast 
reduction surgery, and these factors are not limited to; relieving lower back pain or stasis 
ulcers; improving sports performance or ability to breathe; augmentation as part of gender 
reassignment surgery, or many other various psychological or social reasons. Information 
as to the women’s’ personal motivations for the elective procedure may not be directly 
related to breast cancer risk, but data on these determinants was not provided. As our study 
is concerned with premenopausal breast cancer risk, any additional factors that would 
directly influence breast cancer risk such as breast density cannot be controlled for, and 
therefore may contribute to bias. Hence, there may be significant differences between our 
cohort of cancer-free women and the general population. Due to these concerns, we cannot 
eliminate the possibility that these tissue samples may have been from women who are at 
an increased risk of breast cancer, which would skew our results. 
In addition, BMI is not an accurate indicator of fat deposition or metabolic activity. 
Some overweight and obese individuals exhibit “metabolically healthy” profiles, despite 
presenting with higher general adiposity. Without the accompaniment of biomarkers for 
metabolic function, no assumptions could be made as to the participants’ overall health 
status. The lack of data pertaining to body fat distribution further limits our ability to 
conjecture on the relationship between the more nuanced aspects of bodyweight, folate, 
epigenetic status and premenopausal BC risk.  
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Another limitation of our study is related to our gene selection process. Gene 
selection for our assay was based on a scan of the existing literature. Though the field of 
epigenetics is nearing its hundredth birthday, investigations into the methylation patterns 
of specific cancer types are still quite young. Consequently, few systematic reviews on the 
epigenetic profiles of premenopausal breast cancer exist. The frequency and strength of 
support for evidence on the differential methylation of a particular epiobesigenic gene, 
outside of the most classically investigated such as BRCA1 and BRCA2 or RASSF1A, is 
limited. Many types of genes are strongly implicated with differential methylation levels 
by bodyweight, or folate status, but not for both factors as well as menopausal-specific BC. 
Going further, a more robust and objective screening method for gene inclusion should be 
utilized, strengthening the likelihood of finding a meaningful association between 
epigenetic signature and status. 
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CHAPTER 7 
CONCLUSIONS 
 
7.1 Implications 
Because of the associated risks with increased bodyweight, such as cardiovascular 
disease, stroke, type 2 diabetes mellitus and other metabolic perturbations, our current 
level of understanding cannot support the recommendation of overweight or obesity for 
premenopausal breast cancer risk reduction. Though our study is the first to describe a 
linear relationship between bodyweight as measured by BMI, mammary tissue folate 
status and increased global methylation, investigations into other candidate markers and 
cellular processes are first needed to delineate this causal pathway. For example, 
aberrations in reactive oxidative species production, dysfunctional glucose or lipid 
metabolism, and immune cell function are common in the pro-inflammatory state of 
obesity.  Many critical components of normal one carbon metabolism and DNA 
epigenetic modification are inexorably connected to normal cell functioning, and are 
thus, affected by the overweight or obese state. As such, several lines of inquiry remain 
open for investigation with regard to premenopausal breast cancer risk and its 
relationship to bodyweight and tissue folate status.  
 
7.2 Future Research Recommendations 
The body of peer-reviewed literature on this subject is, at present, insufficient. 
Though a fully powered, randomized control trial on the effects of these factors would 
provide adequate evidence to support new recommendations for premenopausal BC risk 
reduction related to increased bodyweight, further epidemiological studies are first 
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warranted. As stated above, our study uses some of the most widely accepted laboratory 
techniques in biomedical nutrition research, but our sample size is quite limited.  
Conducting a similar line of inquiry on a larger, more representative cohort would 
significantly improve generalizability. Equally important, the inclusion of data on other 
factors such as personal reasoning for the elective mammoplasty, would improve 
statistical power by reducing the potential for confounding. The addition of the 
descriptive data that is included in larger cohort studies, such as information on lifestyle 
factors (physical activity levels, dietary patterns, socioeconomic status) as well as more 
detailed analyses of body fat disposition would shed additional light onto this 
relationship. Controlling for several other variables would be necessary to provide the 
basis for a clinical trial, and in turn, adequate evidence to support tailored 
recommendations with regard to bodyweight status. 
 
7.3 Conclusions 
In conclusion, this study demonstrated that, in the normal mammary tissue from 
premenopausal women, obesity is associated with increased folate status, genome-wide 
DNA methylation and SFRP1 gene expression. These findings support our initial 
hypothesis and provide evidence toward weight-related folate metabolism and epigenetic 
changes as one of the driving factors behind the protective effect of obesity on 
premenopausal breast cancer. Whether there are optimal circumstances or periods for 
potential dietary or lifestyle interventions to promote the protective effects of overweight 
and obesity on premenopausal breast cancer remain to be illuminated. 
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